Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) shot up 25% during trading on Thursday . The company traded as high as C$0.36 and last traded at C$0.35. 1,444,856 shares were traded during trading, an increase of 111% from the average session volume of 684,559 shares. The stock had previously closed at C$0.28.
Hemostemix Stock Up 7.1 %
The firm has a 50-day moving average price of C$0.13 and a two-hundred day moving average price of C$0.09. The company has a market capitalization of C$32.67 million, a P/E ratio of -18.75 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- How to Use the MarketBeat Dividend Calculator
- Bloom Energy: Powering the Future With Decentralized Energy
- Why is the Ex-Dividend Date Significant to Investors?
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
